Phase 1 Trial of CRISPR-Cas9 Gene Editing Targeting <i>ANGPTL3</i>

Editing of <i>ANGPTL3</i> was associated with few adverse events and resulted in reductions from baseline in ANGPTL3 levels. (Funded by CRISPR Therapeutics; Australia New Zealand Clinical Trials Registry number, ACTRN12623000809639.).